logo
Book a meeting
GENFIT

Genfit

Biotechnology, 45 Prospect St, Loos, Massachusetts, 02139, United States, 51-200 Employees

genfit.com

  • facebook
  • twitter
  • LinkedIn

phone no Phone Number: 33*********

Who is GENFIT

GENFIT is a late-stage biopharmaceutical company dedicated to improving the lives of patients with rare and severe liver diseases characterized by high unmet medical needs. GENFIT is a pi...

Read More

lock icon Get Full Access
map
  • 45 Prospect St, Loos, Massachusetts, 02139, United States Headquarters: 45 Prospect St, Loos, Massachusetts, 02139, United States
  • 1999 Date Founded: 1999
  • 51-200 Employees: 51-200
  • dollar-icon Revenue: $10 Million to $25 Million
  • tech-icon Active Tech Stack: See technologies

industries-icon Industry: Biotechnology

SIC SIC Code: 2834 | NAICS Code: 325412 | Show More

checked-icon Does something look wrong? Fix it. | View contact records from GENFIT

GENFIT Org Chart and Mapping

Employees
Benjamin Capellari

Benjamin Capellari

Human Resources Manager

Genfit Corp

Genfit Corp

Office Manager

Joan Moore

Joan Moore

Clinical Project Manager

Ryan Trificana

Ryan Trificana

Gym Owner

See Full Org Chart arrow
email-formate-icon
View Email Formats for GENFIT
arrow
signout-image
You are signed out

Sign in to CIENCE GO Data to uncover contact details

Join Now

crown-icon Free credits every month

Frequently Asked Questions Regarding GENFIT

Answer: GENFIT's headquarters are located at 45 Prospect St, Loos, Massachusetts, 02139, United States

Answer: GENFIT's phone number is 33*********

Answer: GENFIT's official website is https://genfit.com

Answer: GENFIT's revenue is $10 Million to $25 Million

Answer: GENFIT's SIC: 2834

Answer: GENFIT's NAICS: 325412

Answer: GENFIT has 51-200 employees

Answer: GENFIT is in Biotechnology

Answer: GENFIT contact info: Phone number: 33********* Website: https://genfit.com

Answer: GENFIT is a late-stage biopharmaceutical company dedicated to improving the lives of patients with rare and severe liver diseases characterized by high unmet medical needs. GENFIT is a pioneer in liver disease research and development with a rich history and strong scientific heritage spanning more than two decades. Its capacity to develop high potential assets, from early-stages to late development and pre-commercialization stages, is illustrated through the successful 52-week readout of its Phase 3 trial (ELATIVE) evaluating elafibranor in Primary Biliary Cholangitis (PBC). Today, GENFIT has a diversified R&D pipeline covering several therapeutic areas: five programs in acute on chronic liver failure (ACLF) are in clinical stages (Phase 2) and pre-clinical stages, including hepatic encephalopathy (HE), one of the main complications of ACLF; a Phase 2 clinical program targeting cholangiocarcinoma; and a preclinical program targeting urea cycle disorders (UCD) and organic acidemias (OA). GENFITs pipeline also includes a diagnostic franchise focused on Metabolic dysfunction-associated steatohepatitis (MASH, formerly known as nonalcoholic steatohepatitis or NASH) and ammonia. GENFIT has facilities in Lille and Paris (France), Zurich (Switzerland) and Cambridge, MA (USA). GENFIT is a publicly traded company listed on the Nasdaq Global Select Market and on compartment B of Euronexts regulated market in Paris (Nasdaq and Euronext: GNFT). In 2021, IPSEN became one of GENFITs largest shareholders and holds 8% of the companys share capital.

Answer:

Premium Sales Data for Prospecting

  • Sales data across over 200M records

  • Up-to-date records (less decayed data)

  • Accurate Email Lists (real-world tested)

  • Powerful search engine and intuitive interface

lock icon Get Full Access